Maples, Kathryn T. http://orcid.org/0000-0003-1075-0959
Hall, Kevin H. http://orcid.org/0000-0002-9412-4025
Joseph, Nisha S.
Hofmeister, Craig C. http://orcid.org/0000-0003-4816-1607
Gupta, Vikas http://orcid.org/0000-0002-8980-2338
Dhodapkar, Madhav V. http://orcid.org/0000-0002-8249-5988
Kaufman, Jonathan L. http://orcid.org/0000-0002-5687-6429
Nooka, Ajay K. http://orcid.org/0000-0003-4165-6869
Lonial, Sagar http://orcid.org/0000-0002-8322-9323
Article History
Received: 20 December 2022
Revised: 7 February 2023
Accepted: 10 February 2023
First Online: 20 February 2023
Competing interests
: MD serves as Consultant for Amgen, Celgene, Janssen, Kite Pharma, lava therapeutics, and Roche/Genentech. CH receives research funding from Bristol-Myers Squibb, Celgene, and Cellularity and is a Consultant for Celgene, Imbrium, Janssen, Karyopharm, Nektar, Oncopeptides, and Sanofi Pasteur. JK receives research funding from Abbvie/Genentech, Amgen, Bristol-Myers Squibb, Gelgene, Fortis Therapeutics, Janssen, Merck, and Sutro Biopharm, Inc and is a Consultant for Amgen, Bristol-Myers Squibb, Celgene, Janssen, Karyopharm Therapetuics, Sanofi, Takeda, Ecnofarma, and TG Therapeutics. SL receives research funding from Bristol-Myers Squibb, Celgene, and Takeda. He is a Consultant for Abbvie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Juno Therapeutics, Merck, Novartis, and Takeda. KM has served as Consultant for Janssen. AN receives research funding from Amgen, Janssen, and Takeda. He is a Consultant for Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Oncopeptides, Sanofi Pharmaceuticals, and Takeda.